It has taken longer than expected but AstraZeneca PLC has now received European approval for Lokelma (sodium zirconium cyclosilicate), which will go head-to-head in the hyperkalemia space with Vifor Pharma Group's Veltassa (patiromer).
The European Commission's green light for Lokelma, previously known as ZS-9, comes two months after the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion of the drug for the treatment of adults with hyperkalemia, a condition characterized by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?